A novel method for the quantification of vanzacaftor, deutivacaftor, lumacaftor, elexacaftor, tezacaftor, ivacaftor, and selected metabolites in human plasma using liquid chromatography–tandem mass spectrometry

BACKGROUND: Cystic fibrosis transmembrane conductance regulator modulators (CFTRm) have revolutionized the care of patients with cystic fibrosis. There are several clinical justifications for CFTRm therapeutic drug monitoring. To facilitate the implementation of this service, we developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for quantifying CFTRm concentrations in human plasma. METHODS: A high-throughput LC-MS/MS assay was developed for the simultaneous quantification of current and emerging CFTRm, including deutivacaftor, vanzacaftor, ivacaftor, lumacaftor, tezacaftor and elexacaftor, along with major metabolites (hydroxymethyl-ivacaftor, ivacaftor-carboxylate, tezacaftor-M1, and elexacaftor-M23). Sample preparation involved protein precipitation using 5 μL plasma, ensuring efficiency and minimal sample requirement. Chromatographic separation was achieved using a C18 column. Detection was performed via positive electrospray ionization in multiple-reaction-monitoring mode, with stable isotope-labeled internal standards. The instrument runtime was 3.5 minutes, supporting rapid analysis for a high-throughput laboratory. RESULTS: The assay demonstrated a linear range of 0.01 to 10 mg/L for all analytes. Method validation demonstrated high accuracy and precision. Stability studies indicated that all analytes remained stable in plasma under a range of tested conditions. CONCLUSIONS: This validated LC-MS/MS method is robust, sensitive, and suitable for routine clinical application. The short runtime and minimal sample volume support its use in high-throughput settings.

Authors

Institutions

Publication Details

Journal
Bioanalysis
Published
2026-11-17
DOI
https://doi.org/10.1080/17576180.2026.2763324
Primary Topic
Analytical Methods in Pharmaceuticals
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A novel method for the quantification of vanzacaftor, deutivacaftor, lumacaftor, elexacaftor, tezacaftor, ivacaftor, and selected metabolites in human plasma using liquid chromatography–tandem mass spectrometry

Sam Salman, David A. Joyce, Natalia D. Popowicz, Siobhain A. Mulrennan et al.
4 links
Bioanalysis
Analytical Methods in Pharmaceuticals
article

A novel method for the quantification of vanzacaftor, deutivacaftor, lumacaftor, elexacaftor, tezacaftor, ivacaftor, and selected metabolites in human plasma using liquid chromatography–tandem mass spectrometry

Sam Salman, David A. Joyce, Natalia D. Popowicz, Siobhain A. Mulrennan, Sarah Thomas
article en

Abstract

BACKGROUND: Cystic fibrosis transmembrane conductance regulator modulators (CFTRm) have revolutionized the care of patients with cystic fibrosis. There are several clinical justifications for CFTRm therapeutic drug monitoring. To facilitate the implementation of this service, we developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for quantifying CFTRm concentrations in human plasma. METHODS: A high-throughput LC-MS/MS assay was developed for the simultaneous quantification of current and emerging CFTRm, including deutivacaftor, vanzacaftor, ivacaftor, lumacaftor, tezacaftor and elexacaftor, along with major metabolites (hydroxymethyl-ivacaftor, ivacaftor-carboxylate, tezacaftor-M1, and elexacaftor-M23). Sample preparation involved protein precipitation using 5 μL plasma, ensuring efficiency and minimal sample requirement. Chromatographic separation was achieved using a C18 column. Detection was performed via positive electrospray ionization in multiple-reaction-monitoring mode, with stable isotope-labeled internal standards. The instrument runtime was 3.5 minutes, supporting rapid analysis for a high-throughput laboratory. RESULTS: The assay demonstrated a linear range of 0.01 to 10 mg/L for all analytes. Method validation demonstrated high accuracy and precision. Stability studies indicated that all analytes remained stable in plasma under a range of tested conditions. CONCLUSIONS: This validated LC-MS/MS method is robust, sensitive, and suitable for routine clinical application. The short runtime and minimal sample volume support its use in high-throughput settings.

Bioanalysis
The University of Western Australia (AU), Sir Charles Gairdner Hospital (AU), Pathwest Laboratory Medicine (AU)
Good health and well-being
Analytical Methods in Pharmaceuticals
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon